Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Significance
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon May 25, 2022 11:17pm
187 Views
Post# 34708108

RE:RE:RE:Significance

RE:RE:RE:Significance
Doccole wrote: Are we going to Nasdq before the start of phase 2?

will we get fast tracked with our 2nd drug?

What will be the next news drop!?


Likely not before P2 but after P2 and during negotiations ... depends on a few things but that would be my best guess at this time.

Our new Board Chairman knows all about fast-track and breakthrough therapy at Heron.  They got both through the FDA.  I am assuming we will take the dosing and regimen data we are presently collecting and make a submission after that is available.

Tough to say what the next news will be but we're waiting for ...
- commercial business review for OTENA acute (Q2).
- 352 update and all related news - the more I think about it, this could be a very complex approach requiring a pre-op regimen, surgery dosing in IV form and then post-op pain meds - not all 352 but in concert with OTENA.
- fast-tracking and/or breakthrough therapy application.
- chronic pain update.
- IBD update in Q3 - first indication identified and maybe an update on all other indications.
- starting the OTENA P2 in Q4.

IMO - Very Exciting !!!!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities